GLP Watchdog

Drugs and brands

Retatrutide

Every GLP-1 the FDA has approved, and the active ingredient inside each one.

What is Retatrutide?

Eli Lilly's investigational triple agonist (LY3437943), hitting GLP-1, GIP and glucagon receptors.

Phase 2 (NEJM 2023, Jastreboff et al., PMID 37366315) reported up to 24.2% weight reduction at 48 weeks. Phase 3 results are now published: in TRIUMPH-1 (NEJM 2026, PMID 42814954; 2,339 adults with obesity, no diabetes) weight fell 25.0% on 12 mg against 3.9% on placebo at 80 weeks, and TRIUMPH-2 (Lancet 2026, PMID 42810372) reported 18.8% against 5.1% in people with type 2 diabetes. The widely quoted 28.7% figure is from TRIUMPH-4 (obesity with knee osteoarthritis, 12 mg, at 68 weeks) and still comes only from a Lilly topline press release of December 11, 2025. The same release reported dysesthesia in 20.9% of the 12 mg arm against 0.7% on placebo. Not approved. It is sold anyway, as “research peptide”, by sellers this register does not list.

Related reading: Retatrutide: What the Evidence Actually Shows

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where Retatrutide comes up on this site

On GLP Watchdog, Retatrutide comes up in 11 research articles, 6 seller reviews, 21 FDA warning letters and 2 tools. Browse the FDA warning letters.

Research that discusses it

Tools that use it

Seller reviews that mention it

Connected terms

Other terms under Drugs and brands

Where the evidence lives